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ABSTRACT
While it is well established that treatment of cancer patients with 5-Fluorouracil 
(5-FU) can result in immune suppression, the exact function of 5-FU in the modulation 
of immune cells has not been fully established. We found that low dose 5-FU selectively 
suppresses TH17 and TH1 cell differentiation without apparent effect on Treg, TH2, 
and significantly suppresses thymidylate synthase (TS) expression in TH17 and TH1 
cells but has a lesser effect in tumor cells and macrophages. Interestingly, the basal 
expression of TS varies significantly between T helper phenotypes and knockdown 
of TS significantly impairs TH17 and TH1 cell differentiation without affecting the 
differentiation of either Treg or TH2 cells. Finally, low dose 5-FU is effective in 
ameliorating colitis development by suppressing TH17 and TH1 cell development in 
a T cell transfer colitis model. Taken together, the results highlight the importance 
of the anti-inflammatory functions of low dose 5-FU by selectively suppressing TH17 
and TH1 immune responses.
INTRODUCTION
Interleukin (IL)-17 producing T helper cells (TH17), 
are a T helper subtype clearly distinct from T-helper type 
1 (TH1), T-helper type 2 (TH2), and T regulatory (Treg) 
cells, which play an important role in the pathogenesis 
of various inflammatory and autoimmune diseases [1, 
2]. TH17 cell differentiation, survival, and expansion 
depend on many cytokines and transcription factors that 
work in concert to drive the induction of unique program. 
Transforming growth factor β (TGF-β) and Interleukin-6 
(IL-6) have been described as key factors contributing to 
generating de novo TH17 cells [3-5], but other cytokines 
have been shown to have significant auxillary functions 
as well: IL-23 is necessary for TH17 lineage expansion [2, 
6], and IL-21 is also involved the differentiation of TH17 
cells [7-9]. TH17 cells secrete several recognized signature 
cytokines including IL-17A, IL-17F and IL-22 [2, 10-13]. 
Oncotarget19313www.impactjournals.com/oncotarget
The retinoic acid receptor-related orphan nuclear receptor 
(RORγt) has been identified as a critical transcription 
factor for TH17 cell differentiation [14] while several 
other transcription factors including RORα, STAT3, and 
IRF4 have been reported to be involved [1, 14-16]. Other 
metabolism-related factors have also been implicated in 
regulating TH17 differentiation, and have been the focus 
of significant recent studies [17, 18]. For instance, the 
NFAT5 pathway has been shown to upregulate TH17cells 
in response to high salt [19], and the deprivation of 
free amino acids has been reported to bias against TH17 
differentiation [20].
 Accumulating experimental evidence indicates 
that TH17 cells are indeed involved in the pathogenesis 
of various autoimmune/inflammatory diseases [1]. Yen 
at al demonstrated that TH17 cells are responsible for the 
development of colitis in a murine colitis model [21]. 
Leppkes et al indicated that RORγt-expressing TH17 cells 
play a critical role in intestinal inflammation [22]. Fuss et 
al. demonstrated that TH17 cell-inducing IL-23 was highly 
expressed in active Crohn’s patients [23]. However, recent 
reports have indicated that IL-17A plays a protective 
role in T cell-mediated intestinal inflammation [24] and 
a clinical trial showed that treatment with anti-IL-17A 
antibodies was ineffective for IBD patients [25]. As such, 
the exact mechanisms for the TH17 cells contributing to 
the development of inflammatory diseases still need to be 
further explored. 
5-FU, an analogue of uracil, is commonly used as 
a chemotherapeutic drug for treating various kinds of 
tumors, primarily through inhibition of TS [26-29]. Due to 
its structural similarity to uracil, 5-FU and its metabolites 
are readily taken up by many cells. Once inside the cell, 
5-FU can either bind to TS or otherwise be incorporated 
into the dNTP pool [27]. From the nuclear dNTP pool, 
5-FU may induce DNA damage during replication, and 
hinder DNA repair [27]. 5-FU can induce apoptosis in 
cells over time as a result[28, 30]. In colorectal cancer 
(CRC), 5-FU’s efficiency has been linked to cancer cells 
being strongly affected by thymidine starvation and DNA 
damage due to higher rates of replication [17, 31]. As 
part of the FOLFOXIRI treatment regimen, patients may 
receive 1000mg/m2 of 5-FU over 24 hrs to 3200 mg/m2 
over 48 hours, and similar amount in the older FOLFIRI 
regimen [32, 33]. 5-FU may also be provided at 425mg/m2 
as part of adjuvant therapy[34]. Clinically, it is apparent 
that cancer treatment with 5-FU results in the unfortunate 
side effect of broad immune suppression [23, 27]. 
However, the mechanism(s) by which 5-FU modulates 
immune cells have not been fully understood. 
In our present study, we demonstrate that low 
dose 5-FU selectively suppresses TH17 and TH1 cell 
differentiation without major effects on Treg, TH2 cells. 
This effect is not seen with high dose 5-FU, suggesting 
clinical usage and low doses of 5-FU may have different 
immunomodulatory effects. These results highlight the 
importance of anti-inflammatory functions of low dose 
5-FU by selectively suppressing TH17 and TH1 immune 
responses both in vitro and in vivo. 
RESULTS
Low dose 5-FU selectively suppresses TH17 and 
TH1 cell differentiation
5-FU is a first-line chemotherapeutic drug for 
treating CRC, which can result in the side effect of 
immunosuppression. However, the exact mechanism 
by which 5-FU suppresses immune responses remains 
unclear. To investigate the effects of 5-FU on immune cell 
function, we first focused on T helper cells. Naïve CD4+ T 
cells from C57BL/6 mice were primed in vitro for 3 days 
under TH0, TH17, TH1, TH2, or Treg polarizing conditions 
in the presence of 5-FU at different concentrations. 
Interestingly, the frequency of IL-17- and IFN-γ-producing 
cells (IL-17+ cells from 16.9% to 6.0%; IFN-γ+ cells from 
33.1% to 18.1%) decreased following 5-FU treatment in a 
dose-dependent manner, suggesting that 5-FU may have a 
selective effect (Figure 1A). These observations correlated 
with reduced IL-17 and IFN-γ production by TH17 or TH1 
cells treated with 5-FU as determined by ELISA (Figure 
1C). Interestingly, TH2, Treg, TH9, and TH22 differentiation 
were not noticeably affected in T cell cultures treated 
with 5-FU at that lower dosage (Figure 1B, 1C, 1D, 
Supplementary Figure 1A, 1B, 1C, 1D). Furthermore, 
qPCR experiments showed low dose 5-FU significantly 
suppressed mRNA expression of TH17 or TH1-associated 
genes including IL-17, RORγt, IFN-γ, and T-bet (Figure 
1D). 
To rule out the possibility that the reduced TH17 and 
TH1 cell differentiation was due to abnormal cell death 
caused by 5-FU, we analyzed CD4+ T cells from spleens 
as well as lymph nodes of C57BL/6 mice and tumor cell 
lines. Using Annexin V and PI staining for cell death, we 
tested a range of concentrations of 5-FU on naïve T cells 
and tumor cells. T cells were sensitive to 5-FU and as 
the concentration causing clear T cell death is 2.5 µM, 
while the concentration of 5-FU inducing tumor cell death 
is 20 µM (Supplementary Figure 2A, 2B). Since 5-FU 
just caused minimal cell death in naïve T cells up to a 
concentration of 1 µM, we set that as our working dose in 
our subsequent investigations (Supplementary Figure 2A). 
Notably, this dose is much lower than that used clinically, 
and did not lead to tumor cell death (Supplementary 
Figure 2B). Furthermore, 5-FU had no significant effect on 
the expression of IL-10 (Supplementary Figure 3). Thus, 
the decreased TH17 and TH1 cell differentiation induced by 
5-FU was not due to the alterations on IL-10 levels. 
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5-FU alters DNA binding activity in TH17 and TH1 
cells
The data above prompted us to probe for the 
molecular basis for which 5-FU modulates TH17 cell 
differentiation. Since many studies have shown that 
several transcription factors including RORγt, STAT3, 
and IRF4 are important for TH17 cell differentiation[23], 
we hypothesized that low dose 5-FU might affect the 
expression of these transcription factors. To address this, 
naïve CD4+ T cells from C57BL/6 mice were primed in 
vitro for 3 days under TH0 or TH17 polarizing conditions. 
Western blotting experiments showed that the protein 
expression of RORγt was significantly reduced in the 
cells treated with low dose 5-FU (Figure 2A). However, 
the levels of STAT3 and IRF4 protein were comparable 
in the presence or absence of low dose 5-FU (Figure 
2A). In addition, ChIP analysis demonstrated that the 
binding of RORγt to the promoter region of IL-17 gene 
was significantly reduced (Figure 2B). Since STAT3 is 
important for RORγt expression, we next analyzed the 
effects of 5-FU on STAT3 activation. Western blotting 
showed that 5-FU did not affect the levels of STAT3 
expression (Figure 2A, 2C) or nuclear translocation 
(Figure 2C), or STAT3 phosphorylation (Figure 2C). 
However, ChIP experiments showed that the binding 
of STAT3 to the promoter region of RORγt gene was 
significantly reduced (Figure 2D, 2E), suggesting that 
5-FU inhibits STAT3-mediated activation, leading to the 
suppression of TH17 cell differentiation. 
To investigate the molecular mechanism by which 
5-FU affects TH1 cell differentiation, we first examined the 
effects of 5-FU on the expression of STAT4 and T-bet, key 
transcription factors for TH1 cells. Western blotting showed 
that 5-FU had no clear effect on STAT4 expression (Figure 
3A). However, T-bet protein expression was significantly 
reduced in TH1 cells in the presence of 5-FU (Figure 3A), 
Figure 1: Low dose 5-FU selectively suppresses TH17 and TH1 cell differentiation while has no major effects on TH2 
and Treg cell differentiation. A. Naïve CD4+ T cells from C57BL/6 mice were differentiated under TH17 and TH1 polarizing conditions 
respectively in the presence of 5-FU (0.5, 1.0 µM) for 3 days and analyzed through flow cytometry. B. Naïve CD4+ T cells from C57BL/6 
mice were differentiated under TH2 and Treg polarizing conditions respectively in the presence of 5-FU (1.0 µM) for 3 days and analyzed 
through flow cytometry. C. Supernatants from cells cultured in (A) and (B) analyzed via ELISA. D. Cells cultured as in (A) and (B) for 
48 hours; mRNA expression of the indicated genes was determined by qPCR. *p < 0.05, **p < 0 .01, ***p < 0.001 versus cells cultured 
without 5-FU. 
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suggesting that 5-FU inhibits T-bet expression leading to 
the suppression of TH1 cell development. Since STAT4 is 
important for T-bet expression, we next questioned if 5-FU 
influences STAT4 activation. ChIP experiments showed 
that the binding of STAT4 to the promoter region of 
T-bet gene was significantly reduced with 5-FU treatment 
(Figure 3B, 3C), suggesting that 5-FU inhibits STAT4 
DNA binding activity resulting in the suppression of T-bet 
expression and TH1 cell development. 
We then proceeded to analyze whether 5-FU 
modulates posttranslational modification of RORγt or 
T-bet protein resulting in proteasome-mediated protein 
degradation. To test this, we co-transfected T7-RORγt, 
T-bet and HA-tagged ubiquitin overexpression plasmids 
into 293T cells added with 5-FU. 5-FU treatment had no 
significant effect on RORγt or T-bet protein degradation or 
ubiquitination (Figure 4A, 4B, 4C), suggesting that 5-FU 
is not involved in the control of RORγt and T-bet protein 
stability and ubiquitination. 
Figure 2: 5-FU alters STAT3 DNA binding activity in TH17 cells. A. Naïve CD4+ T cells from C57BL/B6 mice cultured in TH17 
polarizing conditions in the presence of 5-FU (1.0 µM) for 3 days prior to western blotting for RORγt and other indicated proteins. B. The 
same cells were cultured for 60 hours, followed by ChIP assay. 3 µg of anti- RORγt antibody or isotype-matched IgG control antibody were 
used in the immunoprecipitation step. qPCR was used to quantify the amount of precipitated DNA with primers flanking the RORγt binding 
the CNS2 of the IL-17 promoter region. C. 293T cells transfected with STAT3 plasmid for 40 hours in the presence of 5-FU (1 µM). The 
cytosolic fraction and nuclear fraction proteins were analyzed via western blotting. Cells were cultured as in (A), with western blotting for 
STAT3 protein phosphorylation and STAT3 protein expression at the times indicated. Cells treated as in (A) analyzed via ChIP assay. 3 µg 
of anti-STAT3 antibody or isotype-matched IgG as control antibody were used in the immunoprecipitation step. qPCR was used to quantify 
the amount of precipitated DNA with primers flanking the STAT3 binding site of the RORγt D. and the CNS2 of the IL-17 (E) promoter 
region. *p < 0.05, **p < 0.01, ***p < 0.001 versus cells cultured without 5-FU. 
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5-FU inhibits TS expression in TH17 and TH1 cells
Since it is well-known that 5-FU can bind directly 
to TS, we next investigated if that binding played a role 
in 5-FU’s selection against TH1 and TH17 cells. Western 
blotting showed that protein expression of TS varies 
significantly between T helper phenotypes, with TH17 cells 
having the highest expression (Figure 5A). TS expression 
increased in all subtypes over the course of polarization, 
and decreased in all phenotypes in the presence of 
5-FU (Figure 5B). Interestingly, 5-FU presence had 
no significant effect on TS expression in tumor cells 
(Figure 5C) and macrophages (Figure 5D). To understand 
the function of TS on T helper cell differentiation, we 
knocked down TS by transfecting TS siRNA in naïve T 
cells and then stimulating them under TH17, TH1, TH2, 
or Treg polarizing conditions. The results showed that 
knockdown of TS significantly suppressed TH17 (IL-17
+ 
cells from 13.8% to 9.3%) and TH1 (IFN-γ
+ cells from 
33.5% to 22.1%) cell polarization without apparent effects 
on TH2 or Treg cell development (Figure 6A, 6B, 6C, 6D, 
6E). ChIP experiments suggest TS may affect STAT3 
DNA binding activity (Figure 6F, 6G). This result further 
demonstrates that TS itself has a role in controlling TH17 
differentiation, ruling out the possibility that 5-FU was 
merely incorporating itself into DNA to induce damage. 
Taken together, the results suggest that low dose 5-FU 
selectively suppresses TH17 and TH1 cell differentiation 
through inhibition of TS expression. 
Given our previous results, we then performed 
further experiments to clarify the role of TS in TH17 and 
Figure 3: 5-FU alters STAT4 DNA binding activity in TH1 cells. A. Naïve CD4+ T cells from C57BL/6 mice were differentiated 
under TH1 polarizing conditions in the presence of 5-FU (1.0 µM) for 3 days and were analyzed by western blotting. **p < 0 .01 versus 
cells not added with 5-FU. Naïve CD4+ T cells from C57BL/6 mice were cultured under TH1-polarizing conditions in the presence of 5-FU 
(1.0 µM) for 60 hours, followed by ChIP assay. 3 µg of anti-STAT4 antibody or isotype-matched IgG as control antibody were used in the 
immunoprecipitation step. qPCR was used to quantify the amount of precipitated DNA with primers flanking the STAT4 binding site of the 
T-bet B. and the IFN-γ C. promoter region. *p < 0 .05 versus cells cultured without 5-FU.
Oncotarget19317www.impactjournals.com/oncotarget
TH1 cells. In particular, we sought to understand if the 
suppression of TH17 and TH1 cells that correlated with 
decreased expression of TS was due to the loss of TS 
enzymatic activity. We isolated CD4+ T cells and polarized 
them with or without 5-FU in the presence or absence 
of thymidylate. Since thymidylate is a product of TS 
activity, we reasoned that it may compensate for loss of TS 
enzymatic activity. Our results indicate that thymidylate is 
indeed capable of rescuing TH17 (IL-17
+ cells from 8.9% 
to 15.3%) and TH1 (IFN-γ
+ cells from 20.2% to 30.7%) 
polarization suppressed by 5-FU (Figure7A, 7B). These 
results were further confirmed via qPCR and ELISA 
(Figure 7A, 7B). Interestingly, TH2 and Treg populations 
were not significantly affected by thymidylate (Figure 7C, 
7D). As such, it is clear that the enzymatic role played by 
TS is a vital component of TH1 and TH17 polarization. 
5-FU modulates TH17 cell differentiation in vivo
TH17 cells are believed to play critical roles in 
the pathogenesis of various autoimmune/inflammatory 
diseases, including multiple sclerosis (MS), inflammatory 
bowel disease (IBD), and rheumatoid arthritis (RA). 
Previous reports have indicated a correlation between 
TH17 activity and IBD pathogenesis. To further assess 
the effects of 5-FU on TH17 cell development in vivo, we 
performed adoptive T cell transfer colitis experiments 
using CD4+CD45Rbhi cells from C57BL/6 mice to 
induce colitis in Rag1-/- mice. Mice in the treatment 
group received low dose 5-FU twice a week for 8 weeks 
while the control group was treated with PBS. While the 
Rag1-/- mice reconstituted with naïve CD4+ T cells lost 
weight continuously, treatment with 5-FU significantly 
Figure 4: The suppression of 5-FU on TH17 and TH1 has no relation to proteasome proteolytic pathway. A. 293T cells 
were co-transfected with HA-tagged ubiquitin (HA-Ub) and T7-tagged RORγt plasmids in the presence of cycloheximide (CHX) and 
5-FU (1 µM) for various time intervals and the cell lysates were collected and RORγt protein expression was analyzed by western blotting. 
B. 293T cells were co-transfected with HA-UB and T-bet plasmids in the presence of CHX and 5-FU (1 µM) for various time intervals 
and the cell lysates were collected and T-bet protein expression was analyzed by western blotting. C. 293T cells were transfected with 
T7-tagged RORγt and HA-Ub overexpression plasmids for 36 hrs. The cell lysates were immunoprecipitated with anti-T7 antibody and 
immunoblotted with anti-HA antibody. The results are representative of three independent experiments.
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improved their condition (Figure 8A). Parallel histologic 
studies of colonic sections from Rag1-/- mice treated with 
5-FU revealed fewer inflammatory cell infiltration and 
significantly lower pathological scores[35] compared to 
mice treated with PBS (Figure 8B, 8C). In addition, mice 
treated with 5-FU had significantly lower percentages 
of IL-17 cells and lower expression of TH17 and TH1 
signature gene expression than PBS treated mice (Figure 
8D, 8E). 
To investigate the toxicity of high and low doses of 
5-FU on intestinal mucosa, C57BL/6 mice were treated 
with either high dose 5-FU (50 mg/kg), low-dose 5-FU 
(10 mg/kg), or PBS as described above. As reported 
previously, high dose 5-FU significantly induced damage 
to intestinal mucosa; however, low dose 5-FU had no 
significant toxicity on intestinal mucosa (Supplementary 
Figure 4A, 4B), further confirming the different effect of 
high and low dose 5-FU on intestinal mucosa. 
DISCUSSION
Chemotherapeutic drugs that are commonly used to 
treat cancer affect not only tumor cells but also immune 
cells, having a crucial impact on antitumor responses 
and disease outcome [27]. Although chemotherapeutics 
combat tumors and lead to their regression, the effects of 
chemotherapeutic drugs on the tumor microenvironment 
and the immune cells are not fully understood. In the 
present study, we found that low dose 5-FU selectively 
suppresses TH17 and TH1 cell differentiation without major 
effect on Treg, TH2, TH9, TH22 cells, suggesting high and 
low dose 5-FU may have different effects on immune 
responses. Furthermore, we found that 5-FU inhibits 
STAT3 binding to the promoter regions of RORγt leading 
to the suppression of RORγt and IL-17 expression. In 
addition, 5-FU also suppresses the binding of STAT4 to 
Figure 5: 5-FU inhibits TS expression in TH17 and TH1 cells. A. Naïve CD4+ T cells from C57BL/B6 mice were differentiated 
under TH0, TH1, TH17, and Treg polarizing conditions respectively for 3 days. The expression of TS protein was analyzed by western 
blotting. *p < 0.05, **p < 0.01, ***p < 0.001 versus control cells. B. Cells cultured as in (A) in the presence of 5-FU (1 µM) for 3 days. 
C. SW620 were cultured in the presence of 5-FU (0.5, 1.5, 10, 20 µM) for 72 hours for western blotting, D. BMDMs were stimulated with 
IFN-gamma (10 ng/ml) and LPS (200 ng/ml) in the presence of 5-FU (0.5, 1.5, 10 µM) for 24 hours for western blotting.
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the promoter region of T-bet, resulting in the modulation 
of TH1 cells. Low dose 5-FU significantly suppresses TS 
expression in TH17 and TH1 cells but it has no effect on TS 
expression in tumor cells and macrophages. Knockdown 
of TS in T cells resulted in the suppression of TH17 
and TH1 cell differentiation and thymidylate can rescue 
TH17 and TH1 polarization suppressed by 5-FU. Finally, 
low dose 5-FU targeting TS is effective in ameliorating 
colitis development by suppressing TH17 and TH1 cell 
development in a T cell transfer colitis model. These 
results suggest that low dose 5-FU selectively suppressing 
TH17 and TH1 immune responses and highlight the 
potential of the anti-inflammatory activity of low dose 
5-FU. 
5-FU is an antimetabolite that kills rapidly 
proliferating cells at clinically used doses by inhibiting 
TS, which limits thymidine availability for DNA synthesis 
[27, 29, 30]. Since 5-FU can induce cell death of many 
Figure 6: Knockdown of the TS suppresses TH17 and TH1 cell differentiation. A. Naïve CD4+ T cells from C57BL/6 mice 
were transfected with TS siRNA or control siRNA and differentiated under TH17 polarizing conditions for 72 hours. Cell lysates were 
analyzed by western blotting. The cells were cultured for 72 hours and then were re-stimulated with PMA/ionomycin for 5 hours, stained 
for intracellular IL-17, and analyzed by flow cytometry, and the supernatants were analyzed for IL-17 by ELISA. ***p < 0.001 versus cells 
transfected with control siRNA. B. Cells treated as in (A) for 48 instead of 72 hours; mRNA expression of indicated genes was determined 
by qPCR. *p < 0.05,***p < 0.001 versus cells transfected with control siRNA. C. Naïve CD4+ T cells from C57BL/6 mice were transfected 
with TS siRNA or control siRNA and differentiated under TH1 polarizing conditions for 72 hours and analyzed by flow cytometry and the 
supernatants were analyzed for IFN-γ by ELISA. ***p < 0.001 versus cells transfected with control siRNA D. Cells as in (C) cultured for 48 
hours; mRNA expression of indicated genes was analyzed by qPCR. *p < 0.05, **p < 0.01 versus cells transfected with control siRNA. E. 
Naïve CD4+ T cells from C57BL/6 mice were transfected with TS siRNA or control siRNA and differentiated under TH2 and Treg polarizing 
conditions for 72 hours and analyzed by flow cytometry. Cells treated as in (A) analyzed via ChIP assay. 3 µg of anti-STAT3 antibody or 
isotype-matched IgG as control antibody were used in the immunoprecipitation step. qPCR was used to quantify the amount of precipitated 
DNA with primers flanking the STAT3 binding site of the RORγt F. and the CNS2 of the IL-17 G. gene promoter region. **p < 0.01 , ***p 
< 0.001 versus cells transfected with control siRNA.
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tumor cell lines, 5-FU alone or in combination with 
other drugs is used to treat cancer in a variety of tissues 
including breast, cervix, colon, stomach, head and neck 
[36], etc. However, in addition to killing tumor cells, 
clinic dose of 5-FU can also eliminate other proliferating 
cells in the bone marrow rapidly resulting in immune 
suppression. Various reports have shown that 5-FU can 
induce cell death of immune cells including T cells, B 
cells and myeloid-derived suppressor cells. These results 
indicate that 5-FU is toxic to immune cells at certain 
concentrations. However, it is still not clear what kinds 
of effects 5-FU will induce at lower concentrations. In the 
present study, we demonstrate that 5-FU at low doses not 
induce T cell death, yet selectively suppresses TH17 and 
TH1 cell differentiation. Taken together, the results suggest 
that low dose 5-FU may play a useful anti-inflammatory 
role by selectively suppressing TH17 and TH1 cells. 
As mentioned previously, 5-FU is a small molecule 
with two well-defined mechanistic pathways: being 
able to irreversibly inhibit TS as well as substituting 
as uracil to prevent effective replication, transcription 
and translation [27]. Our results strongly suggest that 
5-FU’s ability to inhibit TS is at least responsible for its 
selective suppression of TH17 and TH1 cell differentiation 
at low doses. After all, we demonstrate that TS is highly 
expressed by those two T effector cell types, and that 
such expression is conducive to their development. 
These results, however, do not preclude the uracil-mimic 
function of 5-FU from also being significant. Previous 
reports have demonstrated that different T helper subtypes 
may have different rates of metabolism, transcription, 
and translation [17, 18, 31, 37-40]. In particular, T 
effectors such as TH17 and TH1 were shown to have higher 
metabolism and transcription than Tregs. Given that more 
active cell types would also be more susceptible to mimic-
induced instability, it is also possible that 5-FU may be 
Figure 7: 5-FU inhibition is rescued by thymidine. A. Naïve CD4+ T cells from C57BL/6 mice were differentiated under TH17 
polarizing conditions in the presence of 5-FU (1.0 µM) and thymidine (1.0 µM) for 3 days and then were re-stimulated with PMA/
ionomycin for 5 hours, stained for intracellular IL-17, and analyzed by flow cytometry as shown. Supernatants from the cells were saved 
and tested via ELISA. The cells cultured for 48 hours and mRNA expression of the indicated genes was determined by qPCR. B. Repetition 
of (A) using TH1 polarizing conditions. C. Repetition of (A) and (B), except using TH2 polarizing conditions. D. Repetition of (A), (B), and 
(C) with Treg polarizing conditions instead. **p < 0.01, ***p < 0.001 versus cells without thymidine.
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selecting against TH17 and TH1 cells through that manner 
to some extent. While it is theoretically possible that TH17 
and TH1 cells have higher rates of 5-FU incorporation into 
their DNA, such an explanation seems unlikely given the 
unremarkable nature of the promoters of key TH17 and TH1 
proteins as compared to TH2 and Treg gene promoters. It 
may also be possible that high TS expression is indicative 
of the higher overall metabolism within TH17 and TH1 
cells, since TS is in the salvage pathway, and not the 
classical purine catabolism pathway. 
However, given the significant shift in TS expression 
that followed from the addition of 5-FU to TH17 and TH1 
cells, TS is the more likely responsible for changes within 
those cells. If the selective effect of 5-FU on TH1 and 
TH17 cells was primarily a result of induced RNA and 
DNA damage, the rate of apoptosis would be much higher 
than observed. After all, other studies have demonstrated 
that 5-FU’s tumorcidal and general immunosuppressive 
abilities are a result of induced cell death [41-43]. The 
clinical dosage used in such studies, however, is over 
10 times greater than that of our estimated threshold. 
At such high levels, large amount of 5-FU will enter 
the nuclear dNTP pool, and directly interfere with 
replication/transcription/translation. The inhibiting effect 
of 5-FU on TS, while also present, would be completely 
overshadowed. It may well be that at low levels of 5-FU, 
the molecule preferentially binds to TS over joining the 
dNTP pool. Our future experiments will further confirm 
this hypothesis. 
It is well-known that STAT3 is critical for RORγt 
and IL-17 gene expression. In the present study, we 
demonstrated that 5-FU significantly suppressed inhibited 
Figure 8: Low dose 5-FU modulates TH17 cell differentiation in vivo. CD4+CD45Rbhi T cells were purified from C57BL/6mice 
and 5 x 105 cells were injected (i.p.) into recipient Rag1-/- mice. Mice were treated with PBS or 5-FU (at 10 mg/kg body weight) every three 
days. Body weight change was monitored every week for 8 weeks. A. Changes in body weight of Rag1-/- mice (n = 5-6 mice per group) 
after transfer were recorded. ***p < 0.001 versus recipients of PBS treated group. B. Morphology of intestines and disease scores, *p < 0.05 
versus recipients of PBS group; C. sections of colons with colitis from Rag1-/- mice (n = 5-6 mice in each group) 8 weeks after naïve T cell 
transfer as described above. Scale bar, 100 µM. D. The percentage of IL-17 -producing cells from mesenteric lymph nodes of Rag1-/- mice 
in PBS and 5-FU treated group. **p < 0.01 versus recipients of PBS treated group. E. Related mRNA expression of colon was determined 
by qPCR. *p < 0.05, versus recipients of PBS treated group.
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STAT3 DNA binding activities in TH17 cells. In addition, 
knocking-down TS in T cells significantly reduced STAT3 
DNA binding activity. The results suggest that 5-FU-TS 
axis is clearly involved in the development of TH17 cells. 
However, it is still not clear how 5-FU-TS axis regulate 
STAT3 activation. Our future study will focus on how 
the 5-FU-TS axis regulates STAT3 protein expression, 
phosphorylation and translocation.
Recently, several reports demonstrated that 5-FU 
selectively depletes myeloid derived suppressor cells 
(MDSC), a population of immature myeloid cells that 
can suppress T cells function [44-47]. Bruchard et al has 
shown that high dose 5-FU activates NLRP3-dependent 
inflammasome activity in MDSCs resulting in the 
production of IL-1β which can induce secretion of IL-
17 by CD4+ cells.[47]. Interestingly, we found that low 
dose 5-FU (10 mg/kg) did not induce inflammasome 
activation in MDSCs leading to induction of IL-1β 
compared with high dose (50 mg/kg) in the same tumor-
bearing mouse model (Supplementary Figure 5A, 5B, 5C, 
5D). In addition, low dose 5-FU was not able to induce 
inflammasome activation in macrophages and dendritic 
cells (Supplementary Figure 5E). Our future studies will 
address the difference at the molecular levels between 
clinical usage and low dose of 5-FU in the modulation of 
immune cells. 
As our results demonstrate, 5-FU is effective at 
selecting against TH17 and TH1 cell development in vivo as 
well, leading to significant improvement in the condition 
of mice in colitis models. Given the increasing prevalence 
and paucity of treatment options for IBD, it may serve 
as a useful option to consider. 5-FU has the advantage 
of already being fairly well characterized in terms of 
potential toxicological effects and of being abundantly 
available. As such, one might also consider additional 
possibilities for the use of 5-FU in treating other immune 
disorders as well. For instance, dysregulated TH17 and 
TH1 immune responses have also been implicated to be 
of importance in MS and RA, and it may be that 5-FU 
could similarly ameliorate these conditions through TH17 
and TH1 suppression. Other cell types that are mainly 
dependent on TS expression may also be suppressed 
with 5-FU treatment. Overall, our results demonstrate 
the potential therapeutic value of using a lower dosage 
of a broad immunosuppressant to uncover its selective 
ability and report a difference in the importance of the TS 
pathway among T helper cells that may also be exploitable 
through other strategies. 
MATERIALS AND METHODS
Mice
C57BL/6J and Rag1-/- mice were obtained from 
Jackson laboratory and maintained in the barrier facility 
at the Icahn School of Medicine at Mount Sinai. To induce 
LLC tumor-bearing mice model, 5 x 105 cells LLC cells 
were injected subcutaneously into mice. The animal study 
protocols were approved by the Institutional Animal Care 
and Use Committees of Icahn School of Medicine at 
Mount Sinai and Medical College of Georgia. 
Reagents and antibodies
5-FU (F6627) and Thymidine (T1895) were 
purchased from Sigma-Aldrich. The following Flow 
cytometry antibodies were purchased from BD-
Biosciences (USA), and conjugated to FITC, PE, PE-
Cy5, PE-Cy7, PerCP-Cy5.5, PerCP-eFluor 710, eFluor 
450 or APC: CD45RB (C363.16A), CD4 (L3T4), CD25 
(PC61.5), CD44(1M7), CD62L(MEL-14), CD11b 
(M1/70), IL-17 (TC11-18H10), IFN-γ (XMG1.2), FOXP3 
(FJK-16S) and isotype controls. Antibodies for RORγ 
(B2D), Gr1 (RB6-8C5) and IL-4 (11B11) were purchased 
from eBioscience. FITC Annexin V Apoptosis Detection 
Kit I (2293683) was purchased from BD Phamingen. 
Anti-RORγt, anti-T-bet (MBL), anti-Thymidylate 
Synthase, anti-STAT3, anti-pSTAT3, anti-STAT4 (Cell 
Signaling), anti-Caspase 1 (Millipore), anti-HA and anti-
β-actin (Sigma) antibodies for western blotting were used 
according to the manufacturers’ instructions. Secondary 
antibodies were from Santa Cruz Biotechnology, Inc.
CD4+ T cell preparation and differentiation in 
vitro
Naive CD4+ T cells (CD62L+CD44lo) were prepared 
by fluorescence-activated cell sorting from spleens and 
lymph nodes of C57BL/6 mice. The sorted cells were 
primed for 96 hrs with anti-CD3 (1 µg/ml; 145-2C11; BD 
Biosciences) and soluble anti-CD28 (2 µg/ml; 37.51; BD 
Biosciences). Cells stimulated under neutral conditions 
were defined as TH0 cells. Cells were stimulated to 
differentiate into TH1 cells by supplementation with IL-12 
plus anti-IL-4 or into TH2 cells by supplementation with 
IL-4 and anti-IFN-γ. For TH17 cell differentiation, cells 
were stimulated with transforming growth factor-β1 (5 ng/
ml), IL-6 (20 ng/ml) and IL-23 (10 ng/ml; all from R&D 
Systems) and into Treg cells by supplementation with 
transforming growth factor-β1 (15 ng/ml).
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Preparation of bone marrow derived macrophages
Bone marrow (BM) cells were isolated from tibias 
and femurs of C57BL/6 mice and the cells were cultured 
in complete DMEM supplemented with GM-CSF (10 ng/
ml). On day 6 or 7, bone marrow derived macrophages 
(BMDMs) were harvested and then seeded in fresh 
complete DMEM medium at a density of 2 x 106 cells/ml 
for experiments. 
Intracellular staining and flow cytometry
For T cells, cells were stimulated with PMA and 
ionomycin for 5 hrs in the presence of brefeldin A prior 
to intracellular staining. Cells were fixed with IC Fixation 
Buffer (BD Bioscience), incubated with permeabilization 
buffer, and stained with antibodies. For macrophages, 
bone marrow derived macrophages were activated with 
LPS (200 ng/ml) plus IFN-gamma (10 ng/ml) overnight 
and brefeldin A was added to the culture for 5 hrs prior to 
intracellular staining. Flow cytometry was performed on a 
FACS Calibur (BD Biosciences).
Transfection and luciferase reporter assay
For each transfection, 2.0 µg of plasmid was mixed 
with 100 µl of DMEM (without serum and antibiotics) and 
4.0 µl of LipofectamineTM 2000 reagent. The mixture was 
incubated at room temperature for 20 minutes and added 
to 12-well plates containing cells and complete medium. 
The cells were incubated for 30 hrs and harvested using 
reporter lysis buffer (Promega) for determination of 
luciferase activity. Cells were co-transfected with a 
β-galactosidase reporter plasmid to normalize experiments 
for transfection efficiency. 
Chromatin immunoprecipitation (ChIP) assay
The ChIP procedure was performed using an 
assay kit following the manufacturer’s instruction (EMD 
Millipore). Briefly, TH17 and TH1 cells were cross-linked 
by 1% formaldehyde for 10 min at 37°C. Nuclei were 
prepared and subjected to sonication to obtain DNA 
fragments. Chromatin fractions were precleared with 
protein A-agarose beads followed by immunoprecipitation 
overnight at 4°C with 3 µg of anti-STAT3 (Santa Cruz), 
anti-ROR gamma(t) (eBioscience), anti-STAT4 (Santa 
Cruz), or control antibody. Cross-linking was reversed at 
65°C for 4 hrs, followed by proteinase K digestion. DNA 
was purified and subjected to qPCR. The input DNA was 
diluted 200 times prior to PCR amplification. The input 
and immunoprecipitated DNA were amplified by qPCR 
using primers encompassing the STAT3 or STAT4 binding 
sites of the mouse RORγt or T-bet promoter regions. 
Thymidylate synthase SiRNA
Thymidylate Synthase Accell SMART pool small 
interfering RNA (siRNA) was transfected into cells 
according to manufacturer’s (Dharmacon, Thermo 
Scientific) protocol. Briefly, Thymidylate Synthase 
Accell SMART pool siRNA was introduced to murine T 
cells in the Accell delivery medium. Delivery efficiency 
and siRNA specificity were tested by using Accell green 
(FITC) nontargeting control siRNA, GAPDH-specific 
siRNA, and an Accell nontargeting control siRNA 
(Dharmacon).
Cytokine ELISA
Supernatants from cell cultures were collected after 
activation under various conditions and secreted cytokines 
in the supernatants were measured by ELISA kits with 
purified coating and biotinylated detection antibodies: 
anti-IL-17, anti-IFN-γ (R & D systems), anti-IL-9, anti-
IL-22 ,anti-IL-1β (e Bioscience) and anti-IL-4 (BD 
Bioscience). 
RNA isolation and quantitative real-time RT-PCR 
(qPCR)
Total RNA was extracted using an RNeasy plus 
kit (QIAGEN, Valencia, CA) and cDNA was generated 
with an oligo (dT) primer and the Superscript II system 
(Invitrogen, USA) followed by analysis using iCycler PCR 
with SYBR Green PCR master Mix (Applied Biosystems). 
Results were normalized based on the expression of 
ubiquitin. The sequences of primers are shown in 
Supplementary Table 1.
 T cell-transfer colitis
T cell transfer colitis was performed as previously 
described[48, 49]. Briefly, purified CD4+CD45RBhi T cells 
from WT mice were injected intraperitoneally into Rag1-
/- recipients (5 x 105 cells per mouse in 200 µl sterile PBS 
per injection). Mice were weighed every week throughout 
the course of experiments. The degree of inflammation in 
the epithelium, submucosa and submuscularis propria was 
scored separately as described previously[48]. 
Statistical analysis
The results are shown as means ± SD and statistical 
analysis was performed using Student’s t-Test. Where 
more than two groups were compared, one way- ANOVA 
with Bonferroni`s correction were performed. p < 0.05 
were considered statistically significant.
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